Newer molecules in the treatment of schizophrenia: A clinical update - Wikidata - awgldk - TriplyDB

Newer molecules in the treatment of schizophrenia: A clinical update

Newer molecules in the treatment of schizophrenia: A clinical update

http://www.wikidata.org/entity/Q34843883

about

Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics.

P2860

Q35918105-5CDDDDEF-8727-4028-BC75-C378C5296E57 Q53396692-4B20FA51-7442-4835-85F6-DE317A37150B

P2860

Newer molecules in the treatment of schizophrenia: A clinical update

http://www.wikidata.org/entity/Q34843883

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Newer molecules in the treatment of schizophrenia: A clinical update

@ast

Newer molecules in the treatment of schizophrenia: A clinical update

@en

Newer molecules in the treatment of schizophrenia: A clinical update

@nl

type

label

Newer molecules in the treatment of schizophrenia: A clinical update

@ast

Newer molecules in the treatment of schizophrenia: A clinical update

@en

Newer molecules in the treatment of schizophrenia: A clinical update

@nl

prefLabel

Newer molecules in the treatment of schizophrenia: A clinical update

@ast

Newer molecules in the treatment of schizophrenia: A clinical update

@en

Newer molecules in the treatment of schizophrenia: A clinical update

@nl

P1433

Q34843883-147DF983-743B-415E-9DEE-4FB5C79218E5

P1476

Q34843883-4C5D504B-09A0-4352-8451-9A4668FDFEE5

P2093

Q34843883-8F2C1795-176A-44A1-AAFE-0DFD4532D511

Q34843883-A86AEE30-B8BB-4960-8860-C2158ACBF684

Q34843883-ECDAFCAD-E5D1-4C4B-88FF-496CBAAEA98A

P2860

Q34843883-0220698A-4237-468F-A31F-9B923DD51C84

Q34843883-12CC46BA-DF00-4417-9DB6-FAC3B08491E1

Q34843883-16656CF9-F760-43B9-8610-6915D3EE5308

Q34843883-16F972EB-0EBE-49B7-B1C7-9F67BD57061D

Q34843883-17B68244-A02B-45AF-AD48-ADE9D90DEC8E

Q34843883-191C9634-BF29-4CF7-8AF5-0D8B9E36B85A

Q34843883-21FEE03A-57A1-4B77-A800-76318C79DF2A

Q34843883-26B1DDD5-335B-467F-ADAE-AF2C566202C0

Q34843883-2BE9E9B2-5A1B-472C-B8D0-9E44659BE00A

Q34843883-2BF8F6C1-BDDF-47F4-96D1-5B12C8C1E155

P304

Q34843883-C91740A9-1F17-4C9D-85F1-4FEC5D4B65B8

P31

Q34843883-DEB6CB00-C696-4BB7-816A-A914E4971F31

P356

Q34843883-4084EC4C-CE41-460F-A28D-E4ACECC726F3

P407

Q34843883-0F2359A1-1833-43B3-91ED-70254EF0A53A

P433

Q34843883-A067F8F2-D0C4-40D8-9EA6-C2B43257B106

P478

Q34843883-46AA9A5B-9564-4EE9-BE56-B1CED2599996

P577

Q34843883-B57047DA-F1C1-45EA-94D2-EA12C16941C4

P5875

Q34843883-39FCCF70-1925-40E4-9EE5-0E0D0A1B416A

P698

Q34843883-92BA00D2-B2E0-4F2B-ACCC-95596909F226

P921

Q34843883-00CDF8A3-4EAA-48B1-93C6-11B9FDB70073

P932

Q34843883-207A8A38-2001-4826-848A-AED9B2D664C2

P356

0253-7613.77334

P1433

Indian Journal of Pharmacology

P1476

Newer molecules in the treatment of schizophrenia: A clinical update

@en

P2093

Abhishek Ghosh

http://www.w3.org/2001/XMLSchema#string

Kaustav Chakraborty

http://www.w3.org/2001/XMLSchema#string

Surendra Kumar Mattoo

http://www.w3.org/2001/XMLSchema#string

P2860

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia

GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia.

Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence.

Human alpha 7 nicotinic acetylcholine receptor responses to novel ligands.

Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.

SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist.

Talnetant GlaxoSmithKline.

Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers.

P304

105-112

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/0253-7613.77334

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51127133

http://www.w3.org/2001/XMLSchema#string

P698

21572641

http://www.w3.org/2001/XMLSchema#string

P921

P932

3081445

http://www.w3.org/2001/XMLSchema#string